These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38354747)

  • 1. The Relevance of Integrating CYP2C19 Phenoconversion Effects into Clinical Pharmacogenetics.
    Scherf-Clavel M; Weber H; Unterecker S; Frantz A; Eckert A; Reif A; Deckert J; Hahn M
    Pharmacopsychiatry; 2024 Mar; 57(2):69-77. PubMed ID: 38354747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study.
    Scherf-Clavel M; Frantz A; Eckert A; Weber H; Unterecker S; Deckert J; Reif A; Hahn M
    Int J Clin Pharm; 2023 Oct; 45(5):1107-1117. PubMed ID: 37166747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age of onset for increased dose-adjusted serum concentrations of antidepressants and association with sex and genotype: An observational study of 34,777 individuals.
    Tveit K; Hermann M; Nilsen RM; Wallerstedt SM; Rongve A; Molden E; Hole K
    Eur J Clin Pharmacol; 2024 Mar; 80(3):435-444. PubMed ID: 38197945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups.
    Waade RB; Hermann M; Moe HL; Molden E
    Eur J Clin Pharmacol; 2014 Aug; 70(8):933-40. PubMed ID: 24858822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Pharmacokinetic Gene Variation on Therapeutic Drug Levels and Antidepressant Treatment Response.
    Scherf-Clavel M; Weber H; Wurst C; Stonawski S; Hommers L; Unterecker S; Wolf C; Domschke K; Rost N; Brückl T; Lucae S; Uhr M; Binder EB; Menke A; Deckert J
    Pharmacopsychiatry; 2022 Sep; 55(5):246-254. PubMed ID: 35839823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis.
    Milosavljevic F; Bukvic N; Pavlovic Z; Miljevic C; Pešic V; Molden E; Ingelman-Sundberg M; Leucht S; Jukic MM
    JAMA Psychiatry; 2021 Mar; 78(3):270-280. PubMed ID: 33237321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined effect of CYP2C19 and CYP2D6 genotypes on escitalopram serum concentration and its metabolic ratio in a European patient population.
    Faraj P; Haslemo T; Tran JP; Stingl J; Molden E; Hole K
    Br J Clin Pharmacol; 2024 Oct; 90(10):2630-2637. PubMed ID: 38925553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pitfalls and challenges associated with phenoconversion in forensic toxcicology.
    Drevin G; Picard N; Jousset N; Briet M; Abbara C
    Forensic Sci Int Genet; 2021 Mar; 51():102433. PubMed ID: 33278816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort.
    Kringen MK; Bråten LS; Haslemo T; Molden E
    J Clin Psychopharmacol; 2020; 40(2):137-144. PubMed ID: 32134850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype.
    van der Weide J; van Baalen-Benedek EH; Kootstra-Ros JE
    Ther Drug Monit; 2005 Aug; 27(4):478-83. PubMed ID: 16044105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers.
    Steimer W; Zöpf K; von Amelunxen S; Pfeiffer H; Bachofer J; Popp J; Messner B; Kissling W; Leucht S
    Clin Chem; 2004 Sep; 50(9):1623-33. PubMed ID: 15205367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetic Factors Influence Escitalopram Pharmacokinetics and Adverse Events in Youth with a Family History of Bipolar Disorder: A Preliminary Study.
    Honeycutt DC; Blom TJ; Ramsey LB; Strawn JR; Bruns KM; Welge JA; Patino LR; Singh MK; DelBello MP
    J Child Adolesc Psychopharmacol; 2024 Feb; 34(1):42-51. PubMed ID: 38377518
    [No Abstract]   [Full Text] [Related]  

  • 13. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs.
    Brouwer JMJL; Nijenhuis M; Soree B; Guchelaar HJ; Swen JJ; van Schaik RHN; Weide JV; Rongen GAPJM; Buunk AM; de Boer-Veger NJ; Houwink EJF; van Westrhenen R; Wilffert B; Deneer VHM; Mulder H
    Eur J Hum Genet; 2022 Oct; 30(10):1114-1120. PubMed ID: 34782755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The interplay between pharmacogenetics, concomitant drugs and blood levels of amitriptyline and its main metabolites.
    Mifsud Buhagiar L; Casha M; Grech A; Serracino Inglott A; LaFerla G
    Per Med; 2022 Mar; 19(2):113-123. PubMed ID: 35118877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2C19-Guided Escitalopram and Sertraline Dosing in Pediatric Patients: A Pharmacokinetic Modeling Study.
    Strawn JR; Poweleit EA; Ramsey LB
    J Child Adolesc Psychopharmacol; 2019 Jun; 29(5):340-347. PubMed ID: 30817183
    [No Abstract]   [Full Text] [Related]  

  • 16. Associations of antidepressants and antipsychotics with lipid parameters: Do
    Richards-Belle A; Austin-Zimmerman I; Wang B; Zartaloudi E; Cotic M; Gracie C; Saadullah Khani N; Wannasuphoprasit Y; Wronska M; Dawda Y; Osborn DP; Bramon E
    J Psychopharmacol; 2023 Apr; 37(4):396-407. PubMed ID: 36772859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiologically Based Pharmacokinetic Modeling to Unravel the Drug-gene Interactions of Venlafaxine: Based on Activity Score-dependent Metabolism by CYP2D6 and CYP2C19 Polymorphisms.
    Shen C; Yang H; Shao W; Zheng L; Zhang W; Xie H; Jiang X; Wang L
    Pharm Res; 2024 Apr; 41(4):731-749. PubMed ID: 38443631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escitalopram and Sertraline Population Pharmacokinetic Analysis in Pediatric Patients.
    Poweleit EA; Taylor ZL; Mizuno T; Vaughn SE; Desta Z; Strawn JR; Ramsey LB
    Clin Pharmacokinet; 2023 Nov; 62(11):1621-1637. PubMed ID: 37755681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy.
    Steimer W; Zöpf K; von Amelunxen S; Pfeiffer H; Bachofer J; Popp J; Messner B; Kissling W; Leucht S
    Clin Chem; 2005 Feb; 51(2):376-85. PubMed ID: 15590749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
    de Leon J; Susce MT; Murray-Carmichael E
    Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.